United Therapeutics Corporation or Viatris Inc.: Who Invests More in Innovation?

Comparing R&D investments: United Therapeutics vs. Viatris

__timestampUnited Therapeutics CorporationViatris Inc.
Wednesday, January 1, 2014242549000581800000
Thursday, January 1, 2015245098000671900000
Friday, January 1, 2016147600000876700000
Sunday, January 1, 2017264600000857900000
Monday, January 1, 2018357900000822200000
Tuesday, January 1, 20191182600000778200000
Wednesday, January 1, 2020357700000512600000
Friday, January 1, 2021540100000681000000
Saturday, January 1, 2022322900000662200000
Sunday, January 1, 2023408000000910700000
Loading chart...

In pursuit of knowledge

Innovation Investment: A Tale of Two Companies

In the competitive landscape of the pharmaceutical industry, innovation is key. United Therapeutics Corporation and Viatris Inc. have been at the forefront of this race, investing heavily in research and development (R&D) over the past decade. From 2014 to 2023, Viatris Inc. consistently outpaced United Therapeutics in R&D spending, with an average annual investment of approximately $735 million, compared to United Therapeutics' $407 million. Notably, in 2019, United Therapeutics made a significant leap, increasing their R&D expenses by over 230% compared to the previous year, reaching a peak of $1.18 billion. Meanwhile, Viatris maintained a steady investment, peaking at $911 million in 2023. This strategic focus on innovation underscores the companies' commitment to advancing medical breakthroughs and maintaining a competitive edge in the market.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025